Article

Neuroprotective implant for treatment of glaucoma in phase II trial

Author(s):

Julianne Mobilian
Conferences|ASCRS

Here's the latest innovations at Neurotech Pharmaceuticals, Inc. 

Rich Small, CPA, CEO of Neurotech Pharmaceuticals, Inc., shares what's in the pipeline for retina, glaucoma therapies. 

Related Videos
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Related Content
Retinal detachment risk after B1KPro
February 22nd 2025

Retinal detachment risk after B1KPro

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks
February 21st 2025

Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

(Image credit: AdobeStock/InsideCreativeHouse)
February 19th 2025

Alcon announces US launch of Voyager direct selective laser trabeculoplasty device

Shaping the future of retinal therapy
February 19th 2025

Shaping the future of retinal therapy

© 2025 MJH Life Sciences

All rights reserved.